FLT3-ITD – Medxy AI

Noncanonical FLT3-ITD Signaling Drives Immune Evasion via PKCι-STAT1–Mediated CD8+ T-Cell Exhaustion in Acute Myeloid Leukemia

By MedXY 07/15/2026

FLT3-ITD mutations in AML promote immune evasion through a novel PKCι–STAT1 signaling axis that induces CD276-mediated CD8+ T-cell exhaustion, offering a promising target for combined FLT3 and CD276-directed therapies.

Hematology-Oncology news Oncology

S1P Receptor Modulation Restores FLT3 Inhibitor Sensitivity in NRAS-Mutated FLT3-ITD Acute Myeloid Leukemia

By MedXY 06/04/2026

Preclinical data suggest fingolimod and mocravimod can resensitize NRAS-mutated FLT3-ITD AML to FLT3 inhibitors by suppressing ERK-SPHK1-AKT signaling, including activity in patient blasts and an orthotopic mouse model.

Hematology-Oncology news

Comprehensive Mutational Profiling and Clinical Outcomes in Adult AML with NUP98 Rearrangement

By MedXY 05/18/2026

Adult AML with NUP98 rearrangements is a high-risk subtype marked by frequent FLT3-ITD and WT1 mutations, poor survival, and potential benefit from FLT3 inhibitors and stem cell transplant.

Hematology-Oncology news Pediatrics

Allogeneic Stem Cell Transplantation Improves Survival in High-Risk t(6;9) AML, Especially in Younger Patients and Those Achieving CR1

By MedXY 04/27/2026

A large EBMT study shows allo-HSCT provides favorable 2-year survival (65.7%) in high-risk t(6;9) AML, with superior outcomes in CR1 and pediatric/AYA patients. FLT3-ITD positivity triples relapse risk but doesn't impact overall survival.

Hematology-Oncology news

Tailoring Transplant Conditioning and Maintenance Therapy in FLT3-ITD AML: Insights on NPM1 Mutations and Measurable Residual Disease

By MedXY 11/04/2025

Posttransplant gilteritinib greatly benefits FLT3-ITD AML patients with NPM1 comutations, while myeloablative conditioning offers limited advantages over reduced-intensity conditioning in eradicating measurable residual disease.